Radiopharmaceuticals are revolutionizing the way we approach diagnosis, medical treatment, and patient care – Allucent

Allucent recently shared a post on LinkedIn:

“Radiopharmaceuticals are gaining significant attention as this treatment offers key benefits including precision diagnosis, non-invasive procedures, real-time monitoring, and more. These benefits are revolutionizing the way we approach diagnosis, medical treatment, and patient care.

Allucent expert Vanessa Beddo, VP, Global Head of Biostatistics Consulting, spoke at the 2024 Radiopharmaceuticals Summit, where she participated in the conversation about how radiopharmaceuticals can improve patient care and treatment outcomes in clinical trials.

Her insights emphasized the critical role that analysis and study design considerations can play in delivering high-quality, efficient clinical trial results for a successful development program.

Check the recent podcast with Allucent experts Sugato De, MS (VP, Regulatory Strategy, Head of MedTech) and Alex MacDonald, PhD (VP, Model Informed Drug Development), where they dive into the world of antibody-drug conjugates (ADCs) and radionuclide conjugates (RDCs) by exploring both the tremendous growth potential and challenges posed by these targeted oncology therapies.”

Source: Allucent/LinkedIn